- Home
- BLX vs ARQT Comparison
BLX vs ARQT Comparison
Compare BLX & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLX
- ARQT
- Stock Information
- Founded
- BLX 1977
- ARQT 2016
- Country
- BLX Panama
- ARQT United States
- Employees
- BLX N/A
- ARQT N/A
- Industry
- BLX Commercial Banks
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- BLX Finance
- ARQT Health Care
- Exchange
- BLX Nasdaq
- ARQT Nasdaq
- Market Cap
- BLX 1.5B
- ARQT 1.7B
- IPO Year
- BLX N/A
- ARQT 2020
- Fundamental
- Price
- BLX $42.38
- ARQT $15.00
- Analyst Decision
- BLX
- ARQT Strong Buy
- Analyst Count
- BLX 0
- ARQT 6
- Target Price
- BLX N/A
- ARQT $18.80
- AVG Volume (30 Days)
- BLX 130.0K
- ARQT 2.0M
- Earning Date
- BLX 07-22-2025
- ARQT 08-13-2025
- Dividend Yield
- BLX 5.91%
- ARQT N/A
- EPS Growth
- BLX 13.55
- ARQT N/A
- EPS
- BLX 5.60
- ARQT N/A
- Revenue
- BLX $289,499,000.00
- ARQT $212,819,000.00
- Revenue This Year
- BLX $13.23
- ARQT $61.15
- Revenue Next Year
- BLX $7.79
- ARQT $37.98
- P/E Ratio
- BLX $7.55
- ARQT N/A
- Revenue Growth
- BLX 13.37
- ARQT 100.03
- 52 Week Low
- BLX $27.37
- ARQT $7.86
- 52 Week High
- BLX $42.88
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- BLX 61.17
- ARQT 60.23
- Support Level
- BLX $40.14
- ARQT $13.06
- Resistance Level
- BLX $42.62
- ARQT $15.36
- Average True Range (ATR)
- BLX 0.70
- ARQT 0.66
- MACD
- BLX 0.09
- ARQT 0.12
- Stochastic Oscillator
- BLX 84.88
- ARQT 82.57
About BLX Banco Latinoamericano de Comercio Exterior S.A.
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.